Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6541 to 6555 of 7691 results

  1. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued [GID-TAG396]

    Technology appraisal guidance
    Discontinued

  2. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued [GID-TA10711]

    Technology appraisal guidance
    Discontinued

  3. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued [GID-NG10059]

    NICE guideline
    Discontinued

  4. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued [GID-TAG420]

    Technology appraisal guidance
    Discontinued

  5. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued [GID-TAG526]

    Technology appraisal guidance
    Discontinued

  6. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued [GID-TA10157]

    Technology appraisal guidance
    Discontinued

  7. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued [GID-TA10363]

    Technology appraisal guidance
    Discontinued

  8. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued [GID-TA10072]

    Technology appraisal guidance
    Discontinued

  9. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued [GID-TAG424]

    Technology appraisal guidance
    Discontinued

  10. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued [GID-TAG337]

    Technology appraisal guidance
    Discontinued

  11. Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

    Discontinued [GID-TA10070]

    Technology appraisal guidance
    Discontinued

  12. Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

    Discontinued [GID-TA10923]

    Technology appraisal guidance
    Discontinued

  13. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued [GID-TAG421]

    Technology appraisal guidance
    Discontinued

  14. PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

    This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.

    Medtech innovation briefing
    Published
    25 March 2019

  15. UroShield for preventing catheter-associated urinary tract infections (MIB191)

    This advice has been updated and replaced by NICE medical technologies guidance 69.

    Medtech innovation briefing
    Published
    9 September 2019